Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: October 3, 2007
Last updated: October 4, 2007
Last verified: August 2007
Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions

Prostate Carcinoma

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 1950
Study Start Date: June 2005

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with PCa, who will be treated with Zoladex 10,8 SafeSystem based on the current SPC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00540059

Sponsors and Collaborators
Study Director: H Brasch AstraZeneca
  More Information

ClinicalTrials.gov Identifier: NCT00540059     History of Changes
Other Study ID Numbers: Zx-002 
Study First Received: October 3, 2007
Last Updated: October 4, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:
Prostate carcinoma

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on May 26, 2016